IBRN vs PSIL
iShares Neuroscience and Healthcare ETF against AdvisorShares Psychedelics ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
9%
4 shared positions
Fee gap
53 bp
IBRN is cheaper
1-year return gap
7.0 pts
IBRN is ahead
Larger fund
PSIL
$49M
Side by side
| IBRN | PSIL | |
|---|---|---|
| Fund | iShares Neuroscience and Healthcare ETF | AdvisorShares Psychedelics ETF |
| Issuer | iShares | AdvisorShares |
| Category | Biotech & Health Innovation | Cannabis |
| Expense ratio | 0.47% | 1.00% |
| Assets | $6.4M | $49M |
| Average daily dollar volume | $82K | $807K |
| Listed | Aug 24, 2022 | Sep 15, 2021 |
| FrenzyCap score | 37 | 20 |
| 1-month return | −14.9% | −11.9% |
| 3-month return | −16.9% | −6.3% |
| Year to date | −1.8% | +26.8% |
| 1-year return | +13.3% | +6.3% |
| 30-day volatility | 22.0% | 27.4% |
| Worst drawdown, 1 year | −22.8% | −27.6% |
| Trailing 12-month yield | 1.01% | 7.74% |
| Holdings | 81 | 32 |
| Top 10 weight | 41.1% | 69.2% |
| Look-through P/E | — | — |
| Holdings vs fair value | +12.7% | +1.9% |
| Holdings above 200-day average | 33% | 51% |
| Net flow, latest 3 reported months | $0 thru Jul 2026 | +$14M thru Jun 2026 |
| 30-day implied volatility | 35.9% | 49.9% |
| Holdings as of | as of Oct 8, 2026issuer data | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
10% of IBRN · 15% of PSIL
Sector mix of the stock holdings
| Sector | IBRN | PSIL | Gap |
|---|---|---|---|
| Health Care | 80.0% | 86.8% | −6.8% |
| Materials | 2.4% | 0.0% | +2.4% |
More: full overlap table · IBRN holdings · PSIL holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.